Predictors of the Use of Mineralocorticoid Receptor Antagonists in Patients With Left Ventricular Dysfunction Post‐ST‐Segment–Elevation Myocardial Infarction

Background Guidelines recommend mineralocorticoid receptor antagonist (MRA) use in patients with left ventricular ejection fraction ≤40% following a myocardial infarction plus heart failure or diabetes mellitus, based on mortality benefit in the EPHESUS (Eplerenone Post‐Acute Myocardial Infarction Heart Failure Efficacy and Survival Study) trial. The objective of this study was to evaluate the real‐world utilization of MRAs for patients with ST‐segment–elevation myocardial infarction (STEMI) with left ventricular dysfunction. Methods and Results The prospective, population‐based, Vancouver Coastal Health Authority STEMI database was linked with local outpatient cardiology records from 2007 to 2018. EPHESUS criteria were used to define post‐STEMI MRA eligibility (left ventricular ejection fraction ≤40% plus clinical heart failure or diabetes mellitus, and no dialysis‐dependent renal dysfunction). The primary outcome was MRA prescription among eligible patients at discharge and the secondary outcome was MRA prescription within 3 months postdischarge. Of 2691 patients with STEMI, 317 (12%) were MRA eligible, and 70 (22%) eligible patients were prescribed an MRA at discharge. Among eligible patients with no MRA at discharge, 12/126 (9.5%) with documented postdischarge follow‐up were prescribed an MRA within 3 months. In multivariable analysis, left ventricular ejection fraction (odds ratio [OR], 1.55 per 5% left ventricular ejection fraction decrease; 95% CI, 1.26–1.90) and calendar year (OR, 1.23 per year, 95% CI, 1.11–1.37) were associated with MRA prescription at discharge. Other prespecified variables were not associated with MRA prescription. Conclusions In this contemporary STEMI cohort, only 1 in 4 MRA‐eligible patients were prescribed an MRA within 3 months following hospitalization despite high‐quality evidence for use. Novel decision‐support tools are required to optimize pharmacotherapy decisions during hospitalization and follow‐up to target this gap in post‐STEMI care.

[1]  Chen-Tan Lin,et al.  Heart Failure Management Innovation Enabled by Electronic Health Records. , 2020, JACC. Heart failure.

[2]  J. McMurray,et al.  Mineralocorticoid Receptor Antagonists, Blood Pressure, and Outcomes in Heart Failure With Reduced Ejection Fraction , 2020, JACC. Heart failure.

[3]  B. Pitt,et al.  Eplerenone in patients with myocardial infarction and “mid‐range” ejection fraction: An analysis from the EPHESUS trial , 2019, Clinical cardiology.

[4]  L. Lund,et al.  Factors associated with underuse of mineralocorticoid receptor antagonists in heart failure with reduced ejection fraction: an analysis of 11 215 patients from the Swedish Heart Failure Registry , 2018, European journal of heart failure.

[5]  J. H. Patterson,et al.  Medical Therapy for Heart Failure With Reduced Ejection Fraction: The CHAMP-HF Registry. , 2018, Journal of the American College of Cardiology.

[6]  Shubha Bhat,et al.  Outcomes of a Pharmacist-Managed Heart Failure Medication Titration Assistance Clinic , 2018, The Annals of pharmacotherapy.

[7]  Marco Valgimigli,et al.  [2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation.] , 2018, Kardiologia polska.

[8]  J. Singer,et al.  Evolution and Impact of a Regional Reperfusion System for ST-Elevation Myocardial Infarction. , 2016, The Canadian journal of cardiology.

[9]  J. D. de Lemos,et al.  The association of left ventricular ejection fraction with clinical outcomes after myocardial infarction: Findings from the Acute Coronary Treatment and Intervention Outcomes Network (ACTION) Registry-Get With the Guidelines (GWTG) Medicare-linked database. , 2016, American heart journal.

[10]  B. Hemmelgarn,et al.  The Effectiveness of Pharmacist Interventions on Cardiovascular Risk: The Multicenter Randomized Controlled RxEACH Trial. , 2016, Journal of the American College of Cardiology.

[11]  K. Alexander,et al.  Use of aldosterone antagonists at discharge after myocardial infarction: results from the National Cardiovascular Data Registry Acute Coronary Treatment and Intervention Outcomes Network (ACTION) Registry-Get with the Guidelines (GWTG). , 2013, American heart journal.

[12]  K. Swedberg,et al.  Clinical course and predictive value of congestion during hospitalization in patients admitted for worsening signs and symptoms of heart failure with reduced ejection fraction: findings from the EVEREST trial. , 2013, European heart journal.

[13]  Harlan M Krumholz,et al.  2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. , 2013, Circulation.

[14]  Deepak L. Bhatt,et al.  Temporal trends and predictors in the use of aldosterone antagonists post-acute myocardial infarction. , 2013, Journal of the American College of Cardiology.

[15]  E. López-de-Sá,et al.  [Aldosterone receptor antagonist use after myocardial infarction. Data from the REICIAM registry]. , 2011, Revista espanola de cardiologia.

[16]  I. Komenaka,et al.  The effectiveness of grand rounds lectures in a community-based teaching hospital. , 2009, Journal of surgical education.

[17]  G. Filippatos,et al.  Timing of eplerenone initiation and outcomes in patients with heart failure after acute myocardial infarction complicated by left ventricular systolic dysfunction: insights from the EPHESUS trial † , 2009, European journal of heart failure.

[18]  F. Fedele,et al.  Aldosterone receptor blockade in patients with left ventricular systolic dysfunction following acute myocardial infarction. , 2008, Cardiology clinics.

[19]  H. White,et al.  Eplerenone reduces mortality 30 days after randomization following acute myocardial infarction in patients with left ventricular systolic dysfunction and heart failure. , 2005, Journal of the American College of Cardiology.

[20]  G. Lamas,et al.  ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction--executive summary. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to revise the 1999 guidelines for the management of patients wi , 2004, Journal of the American College of Cardiology.

[21]  M. Horie,et al.  Immediate Administration of Mineralocorticoid Receptor Antagonist Spironolactone Prevents Post-Infarct Left Ventricular Remodeling Associated With Suppression of a Marker of Myocardial Collagen Synthesis in Patients With First Anterior Acute Myocardial Infarction , 2003, Circulation.